WilmerHale Advises Apellis Pharmaceuticals in $120M Collaboration With SFJ Pharmaceuticals

WilmerHale Advises Apellis Pharmaceuticals in $120M Collaboration With SFJ Pharmaceuticals

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

On February 28, 2019, Apellis Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals, a global drug development company backed by Blackstone Life Sciences and Abingworth. Apellis is expected to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement.

Steve Barrett and Stuart Falber led the WilmerHale team representing Apellis, along with John Sigel and Byron Crowe.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel